Undoubtedly, the most widely used HER2-targeted agent to date has been trastuzumab (Herceptin®, Basilea, Switzarland), a humanized monoclonal antibody (mAb) approved by the major drug regulatory agencies for the past two decades for the treatment of both early and metastatic BC [5]. The gene discussed is ERBB2; the disease is breast cancer.